1Andersson T.Pharmacokinetics,metabolism and interactions of acid pump inhibitors.Focus on omeprazole[J].Clin Pharmacokinet,1996,31(1):9-28.
2Meyer UA.Metabolic interactions of the proton-pump inhibitors lansoprazole and pantoprazole with other drugs[J].Eur J Gastroenterol Hepatol,1996,8(Suppl 1):S21-S25.
3de Morais SMF,Wilkinson GR,Blaisdell J,et al.The major genetic defect responsible for the polymorphism of S-mephenytoin in humans[J].J Biol Chem,1994,269(22):15419-15422.
4de Morais SMF,Wilkinson GR,Blaisdell J,et al.Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in japanese[J].Mol Pharmacol,1994,46(4):594-598.
5Leiri l,Kubota T,Urae A,et al.Pharmacokinetics of omeprazole(a substrate of CYP2C19) and coparison with two mutant allales,CYP2C19m1 in exon5 and CYP2C19m2 in exon4,in Japanese subjects[J].Clin Pharmacol Ther,1996,59(6)∶647-653.
6Inaba T,Mizuno M,Kawai K,et al.Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype[J].J Gastroenterol Hepatol,2002,17(7)∶748-753.
7Wada F,Murase K,Isomoto H,et al.Polymorphism of CYP2C19 and gastric emptying in patients with proton pump inhibitor-resistant gastric ulcers[J].J Int Med Res,2002,30(4):413-421.
8Yasuda S,Horai Y,Tomono Y,et al.Comparison of the kinetic disposition and metabolism of E3810,a new proton pump inhibitor,and omeprazole in relation to S-mephenytoin 41-hydroxylation status[J].Clin Pharmacol Ther,1995,58(2)∶143-154.
9Thitiphuree S,Talley NJ.Esomeprazole,a new proton pump inhibitor:pharmacological characteristics and clinical efficacy[J].Int J Clin Pract,2000,54(8):537-541.
10Kawaguchi M,Ohnishi A,Humphries T.Concomitant administration of antacid and food do not affect the bioavailability of rabeprazole sodium in normal volunteers(Abstract)[J].Digestion,1998,59(Suppl 3):S76.
